HIV Cure

Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic HIV medication in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for Abacavir, Dolutegravir and Lamivudine tablets, the Mumbai-base drug maker said in a statement. The company's product is a generic equivalent of ViiV Healthcare Company's Triumeq PD tablets for oral suspension, it added. This product would be manufactured at the drug firm's Nagpur facility and will be supplied to low-and middle-income countries, it said. The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen, indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months and weighing at least 6 kg. "The tentative approval from the USFDA for our Abacavir, Dolutegravir and

Deaths from AIDS in the country came down by 79 per cent while HIV infections fell by 44 per cent in 2023 and the country is committed to achieve the United Nations Sustainable Development Goal of eradicating AIDS by 2030, Union Health Minister JP Nadda said on Sunday.He was speaking at a function here on the occasion of World AIDS Day. Nadda said the renewed IDS response measures of 'test and treat' and universal viral load testing will be endorsed and AIDS (Prevention and Control) Act 2017 will be implemented in toto. India has worked out a formula of "95-95-95" in view of the target of eliminating AIDS by 2030, he added. "Ninety-five percent of the patients in the country should know that they are infected with HIV, 95 percent of the patients should get treatment and the "viral load" of 95 percent of the patients should be lessened by antiretroviral therapy medicines," he explained. At present, 81 per cent of patients know they are infected with HIV, 88 per cent patients are ...

Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the United States and European markets in 2022. It is a first-in-class HIV-1 capsid inhibitor

Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries. The company has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement. Lenacapavir is a US Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus a type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally. Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the US and Europe markets in the year 2022. As per the agreement, Dr Reddy's w

Gilead is seeking patents in India for the choline and sodium salt forms of lenacapavir

Lenacapavir drug hailed as 'the closest we have ever been to an HIV vaccine', is currently sold by US pharma major Gilead at Rs $42,250 for the first year

The final report of the UK's infected blood inquiry will be published Monday, nearly six years after it began looking into how tens of thousands of people contracted HIV or hepatitis from transfusions of tainted blood and blood products in the 1970s and 1980s. The scandal is widely seen as the deadliest to afflict Britain's state-run National Health Service since its inception in 1948, with around 3,000 people believed to have died as a result of being infected with the HIV virus and hepatitis, an inflammation of the liver. The report is expected to criticise pharmaceutical firms and medical practitioners, civil servants and politicians, though many have already died given the passage of time. It's also set to pave the way to a huge compensation bill that the British government will be under pressure to rapidly pay out. Had it not been for the tireless campaigners, many of whom saw loved ones die decades too soon, the scale of the scandal may have remained hidden forever. This who

The Delhi High Court will take up and dispose of on priority basis the legal proceedings concerning an HIV positive person whose anonymity and confidentiality shall be strictly maintained. The practice directions' have been issued by the high court, on its administrative side, in compliance with the directions passed by the Supreme Court in a judgment on September 26, 2023. In compliance of the directions passed by the Hon'ble Supreme Court in judgment dated September 26, 2023 in , Hon'ble the Acting Chief Justice has been pleased to issue following directions for compliance by all concerned. In any legal proceeding concerning or relating to an HIV-positive person, the courts shall take up and dispose of the proceeding on priority basis in terms of Section 34(2) of the HIV (Prevention and Control) ACT 2017, the practice directions issued through Delhi High Court Registrar General Kanwaljeet Arora on February 7 said. It further said that courts shall also ensure that the anonymity a

On World AIDS Day, WHO called upon member states, partners and communities in the Southeast Asia Region and around the world to continue fostering collaboration to address the challenges in ending the disease by 2030 and empower communities to lead in shaping the response forward. Globally, an estimated 39 million people are living with HIV. In 2022, around 1.3 million people acquired HIV and around 6,30,000 people died from AIDS-related causes, said Dr Poonam Khetrapal Singh, the WHO Regional Director for South-East Asia. In the South-East Asia Region, an estimated 3.9 million people are living with HIV, accounting for around 10 per cent of the global burden. In 2022, an estimated 1,10,000 people became newly infected with HIV and 85,000 people in the region died of AIDS-related causes. This accounted for over 13 per cent of the global burden of AIDS-related death, Dr Khetrapal Singh said. Over the past decade, the Southeast Asia Region had substantial progress with a remarkable .

South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. Experts see it as a shift in how such countries deal with pharmaceutical behemoths and say it could trigger more efforts to make lifesaving medicines more widely available. In the COVID-19 pandemic, rich countries bought most of the world's vaccines early, leaving few shots for poor countries and creating a disparity the World Health Organization called a catastrophic moral failure. Now, poorer countries are trying to become more self-reliant because they've realized after COVID they can't count on anyone else, said Brook Baker, who studies treatment-access issues at Northeastern University. One of the targets is a drug, bedaquiline, that is used for treating people with drug-resistant versions of tuberculosis. The pills are

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ Ahmedabad

Strides Pharma Science said its step-down wholly-owned subsidiary, has received approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV

The case needs independent verification and it's way too soon to speculate about a possible cure, scientists cautioned

Data from market research firm AIOCD-AWACS shows that sales of oseltamivir (common brand Tamiflu), used against the influenza virus and also for swine flu, went up by 35.8 per cent in April

Domestic players will be free to price it; Dutch firm Mylan also to make the drug in India; no royalty for Gilead as yet

Government has received two types of kits from Guangzhou Wondfo and Zhuhai Livzon to see antibodies in Covid patients

An HIV patient who has received timely treatment can live a normal and long life without progressing to late stage HIV

ViiV Healthcare received a complete response letter from the Food and Drug Administration, which cited "chemistry manufacturing and controls," according to a statement from the HIV unit

If approved by regulators, the medicine will be the first new generation HIV medicine available in baby-friendly form

There are just two cases where the killer disease appears to have been cured. Researchers are also looking for other genes that can block HIV